Search
for
Sort by
Research 751–780 of 1000+
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- Comparative efficacy and safety of platelet-rich plasma (PRP), injectable platelet-rich fibrin (i-PRF) and concentrated growth factors (CGF) for female pattern hair loss (FPHL): a prospective multicenter randomized clinical trial
- Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology
- What to Look for in Red Light Therapy: A Product Guide Backed by Science
- Finasteride Use: Evaluation of Depression and Suicide Risk
- Investigator‐blinded, controlled, and randomized comparative study on 1565 nm non‐ablative fractional laser versus 5% minoxidil for treatment of androgenetic alopecia
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia
- The effectiveness and safety evaluation of hair growth promotor containing teak leaf extract
- Clinical Management of Acral Lick Dermatitis in Dogs with Comparison of Fluoxetine and Clomipramine Treatment
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
- Antihelminthic Drugs
- Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Pegylated-interferon-α<sub>2a</sub>in clinical practice: how to manage patients suffering from side effects
- Sorafenib-Associated Facial Acneiform Eruption
- DERMATOLOGICAL AND SYSTEMIC REACTIONS TO HAIR DYES: CURRENT EVIDENCE AND MANAGEMENT
- Gestational diabetes mellitus and COVID-19, clinical characteristics and review of the literature
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- Scalp Surgery: Anatomic and Biomechanical Considerations
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- Bridging psychoneuroimmunology and homeopathy: Modulating the cellular and emotional cascades in refractory alopecia
- Topical Eflornithine
- Drug-Induced Skin, Nail and Hair Disorders
- Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
- Alopecia areata in 2 patients treated with dupilumab: New onset and worsening
- Nutrition and the deleterious side effects of nutritional supplements